InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
A director at CVS Health Corp bought 30,000 shares at 66.700USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
Our credit view of this issuer reflects its execution risk related to expansion into primary care and its regulatory uncertainty related to PBM and pharmacy business practices.
Moody's Ratings (Moody's) downgraded the ratings of CVS Health Corporation (CVS) including the senior unsecured notes to Baa3 from Baa2; the senior unsecured shelf to (P)Baa3 from (P)Baa2, the junior subordinated notes to Ba1 from Baa3 and the senior unsecured commercial paper rating to Prime-3 from...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Moody's Ratings (Moody's) assigned a Baa3 rating to CVS Health Corporation's (CVS) proposed offering of junior subordinated notes, with this rating immediately placed on review for downgrade. There are no changes to CVS' existing ratings including the Baa2 senior unsecured notes, (P)Baa2 senior unse...
Compares key performance metrics against industry peers.
Our credit view of this issuer reflects good scale and diversity, tempered by cost pressures in the Medicare Advantage business.
Moody's Ratings (Moody's) placed the ratings of CVS Health Corporation (CVS) on review for downgrade. The ratings placed on review include the Baa2 senior unsecured notes, (P)Baa2 senior unsecured shelf and Prime-2 senior unsecured commercial paper rating. Previously, the outlook was negative. The...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Compares key performance metrics against industry peers.
Our credit view of this issuer reflects its solid prescription drug fundamentals, offset by its execution risk related to expansion into primary care.
Moody's Ratings (Moody's) affirmed the ratings of CVS Health Corporation ("CVS") including the Baa2 senior unsecured notes, (P)Baa2 senior unsecured shelf and Prime-2 senior unsecured commercial paper rating. At the same time, we revised CVS's outlook to negative from stable. The affirmation of th...
Compares key performance metrics against industry peers.
Moody's Ratings (Moody's) assigned a Baa2 rating to the new senior unsecured notes issuance of CVS Health Corporation ("CVS"). There are no changes to CVS's existing ratings including the Baa2 senior unsecured long-term rating or the Prime-2 commercial paper rating. The outlook remains unchanged at ...
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
Moody's Ratings ("Moody's") commented on CVS Health Corporation's (Baa2 stable) continuing pressure in its Medicare Advantage business, which prompted a significant downward revision in 2024 earnings guidance. These events are credit negative because of the impact on CVS's financial leverage, with g...
Profit pressures will cause higher leverage, but financial levers and earnings growth in 2025 will benefit credit ratios.
A summary company profile, detailing CVS Health Corporation’s business operations and financial highlights.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.